Developer docs
API playgroundTry for free, no card

Search company profiles

Angiex

Full company profile

uuid0003qfn

Namestring
Angiex
Legal namestring
Angiex Inc.
Websiteurl
angiex.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Angiex is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts, developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for the treatment of solid tumors. Its proprietary Nuclear Delivery Platform exploits the TM4SF1 transmembrane protein's unique intracellular transport pathway — microdomain-enriched vesicles traveling along microtubules from the cell surface to the nucleus — to deliver chemotherapeutic payloads directly to the nuclei of tumor cells and tumor vascular endothelial cells. The lead asset, AGX101, is a TM4SF1-directed ADC with a maytansine-derived tubulin inhibitor payload conjugated via a hydrophilic linker; it is currently in a multi-site US Phase 1 dose-escalation and expansion trial (NCT06440005), with first patient dosed in August 2024. Preclinical data show picomolar IC50s, complete tumor regressions in xenograft models, and a claimed 10-fold improvement in therapeutic margin over Pfizer's earlier TM4SF1 ADC, with no observed overlap in toxicities with standard oncology drugs.

The company's technology targets solid tumors through three mechanisms: vascular injury (depriving tumors of blood supply), direct tumor cell killing of invasive and metastatic TM4SF1-positive cells, and immune activation via conversion of immunologically cold tumors to checkpoint inhibitor-responsive phenotypes. Angiex was founded by Harold Dvorak (discoverer of VEGF) and Shou-Ching Jaminet (discoverer of TM4SF1's role in angiogenesis) together with CEO-founder Paul Jaminet. The company is led by CEO Marty J. Duvall (joined 2022) with Iain Dukes as Executive Chairman, Glen Weiss as CMO, and Shou-Ching Jaminet as CSO. The current revenue model is pre-commercial; Angiex has indicated it may pursue a global pharmaceutical partnership for worldwide commercialization similar to the Daiichi Sankyo/AstraZeneca ADC model, while retaining clinical development and manufacturing internally. To date, the company has raised approximately $76M+ in equity financing, including a $45M Series B led by Presight Capital with Peter Thiel participation (Aug 2021) and a $31M financing completed in November 2025 with Paulson Investment Company as placement agent.

Short descriptiontext

Angiex is a privately held, clinical-stage biopharmaceutical company developing first-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumors, with lead asset AGX101 currently in a US Phase 1 trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology therapeutics, targeted cancer therapy, vascular-targeted biotherapeutics, clinical-stage biopharma
Industry1 code
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Development
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Angiex is developing AGX101 through Phase 1 clinical trials with the intent to commercialize the drug. The company has indicated it may pursue partnership with a global pharmaceutical company for marketing, sales, and distribution, similar to the Daiichi Sankyo/AstraZeneca model for ADCs, while retaining clinical development and manufacturing control internally.

angiex.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Angiex develops first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumor oncology, with lead asset AGX101 (a TM4SF1-directed ADC) currently in Phase 1 clinical trials in the United States. The proprietary Nuclear Delivery Platform delivers chemotherapeutic payloads directly to the nucleus of tumor cells and tumor vasculature endothelial cells via the TM4SF1 transport pathway, enabling dual attack on tumor blood vessels and tumor cells with three mechanisms of action (vascular injury, direct tumor cell killing, immune activation).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Phase 1 dose-escalation and expansion trial initiated with first patient dosed August 7, 2024. Clinical site: NCT06440005 at multiple U.S. locations.
+6 more records
Product overview1 text field

Angiex is developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality. The company's lead product is AGX101, a first-in-class TM4SF1-directed ADC currently in Phase 1 clinical trials for solid tumors. AGX101 is built on Angiex's proprietary Nuclear Delivery Platform™ which exploits a novel TM4SF1 intracellular transport pathway to deliver payloads directly to the nucleus of tumor cells and tumor vasculature. The company also maintains a discovery-stage pipeline of additional ND-ADCs leveraging the same platform and target.

Product and service3 records
1AGX101
CategoryOncology Therapeutics (Antibody-Drug Conjugate)
Description

First-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) for the treatment of solid cancers. Currently in Phase 1 clinical trials. Attacks both tumor cells and tumor vasculature through three mechanisms: vascular injury to deprive tumors of blood supply, activation of anti-tumor immunity, and direct killing of invasive and metastatic tumor cells. Targets TM4SF1, which is highly expressed in tumor cells and tumor vascular endothelial cells but limited in normal adult tissue.

2Nuclear Delivery Platform
CategoryProprietary Drug Discovery Platform
Description

Proprietary technology platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and endothelial cells of tumor blood vessels via TM4SF1's intracellular transport pathway. Enables creation of drugs for solid cancers with exceptional efficacy and therapeutic margin; protected by approximately a dozen patents on novel TM4SF1-directed ADC compositions and methods.

3TM4SF1-Targeted Discovery Pipeline
CategoryOncology Pipeline (Discovery-stage ND-ADCs)
Description

Discovery-stage pipeline of additional Nuclear-Delivered Antibody-Drug Conjugates beyond AGX101, leveraging the same TM4SF1 target and Nuclear Delivery Platform for multiple solid tumor indications.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-08-09
Description

Abzena, a global biopharmaceutical services provider and CDMO, provides critical clinical trial material manufacturing and bioconjugation services for Angiex's AGX101 Phase I clinical trial. Abzena's integrated services including cGMP manufacturing enabled Angiex to advance AGX101 into human trials. CEOs of both companies (Paul Jaminet of Angiex and Matthew Stober of Abzena) appeared jointly on the 'Chats with Chaudhrey' podcast discussing the collaboration.

2Millipore-Sigma (BioReliance End-to-End Solutions)
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2017-08-29
Description

Millipore-Sigma collaborated with Angiex in August 2017 to support clinical readiness of Angiex's lead oncology ADC candidate. This was the first project at Millipore-Sigma's Massachusetts BioReliance End-to-End Solutions center. The collaboration gave Angiex access to end-to-end process development tools, GMP manufacturing process development, education programs, and training. Angiex CEO Paul Jaminet cited Millipore-Sigma's broad process development capabilities as key to accelerating the path to clinic.

angiex.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage ADC company developing next-generation ADCs for solid tumors using proprietary Dolasynthen and Immunosynthen platforms. Closely comparable to Angiex in modality, stage, and solid tumor focus.

TypeBroad incumbent
Description

Global ADC leader with Enhertu (DXd-ADC platform) partnered with AstraZeneca. Directly relevant as the model Angiex explicitly cites for its intended partnership/commercialization strategy and as the dominant player in solid-tumor ADCs.

TypeBroad incumbent
Description

Co-developer of Enhertu and Datroway ADCs with Daiichi Sankyo; the reference commercial partner cited by Angiex. Comparable as a large-cap oncology company with a major ADC franchise in solid tumors.

TypeBroad incumbent
Description

Major ADC player (Padcev) and historically developed a prior TM4SF1-directed ADC that AGX101 was designed to outperform by 10x in therapeutic margin. Highly relevant given direct prior work on the same target.

TypeBroad incumbent
Description

Acquired Immunomedics to commercialize Trodelvy, a leading solid-tumor ADC. Comparable as a large oncology company with an ADC franchise overlapping Angiex's solid-tumor setting.

TypeEmerging player
Description

Emerging clinical-stage ADC company developing differentiated solid-tumor ADCs using proprietary linker chemistries. Comparable in stage and technology-platform approach to Angiex.

TypeEmerging player
Description

Clinical-stage ADC developer with multiple solid-tumor programs in Phase 1/2. Comparable in stage, modality, and solid tumor focus.

TypeEmerging player
Description

Clinical-stage ADC and immuno-oncology company developing solid-tumor ADCs. Comparable as a similarly sized, similarly staged oncology biotech with platform-based ADC ambitions.

TypeEmerging player
Description

Clinical-stage oncology company using a Probody platform to develop masked ADCs and immunotherapies for solid tumors. Comparable in modality, stage, and platform-disciplined pipeline approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Angiex

Oncology Therapeuticsangiex.com

Angiex is a privately held, clinical-stage biopharmaceutical company developing first-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumors, with lead asset AGX101 currently in a US Phase 1 trial.

What Angiex does

Angiex is a privately held, clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts, developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for the treatment of solid tumors. Its proprietary Nuclear Delivery Platform exploits the TM4SF1 transmembrane protein's unique intracellular transport pathway — microdomain-enriched vesicles traveling along microtubules from the cell surface to the nucleus — to deliver chemotherapeutic payloads directly to the nuclei of tumor cells and tumor vascular endothelial cells. The lead asset, AGX101, is a TM4SF1-directed ADC with a maytansine-derived tubulin inhibitor payload conjugated via a hydrophilic linker; it is currently in a multi-site US Phase 1 dose-escalation and expansion trial (NCT06440005), with first patient dosed in August 2024. Preclinical data show picomolar IC50s, complete tumor regressions in xenograft models, and a claimed 10-fold improvement in therapeutic margin over Pfizer's earlier TM4SF1 ADC, with no observed overlap in toxicities with standard oncology drugs.

The company's technology targets solid tumors through three mechanisms: vascular injury (depriving tumors of blood supply), direct tumor cell killing of invasive and metastatic TM4SF1-positive cells, and immune activation via conversion of immunologically cold tumors to checkpoint inhibitor-responsive phenotypes. Angiex was founded by Harold Dvorak (discoverer of VEGF) and Shou-Ching Jaminet (discoverer of TM4SF1's role in angiogenesis) together with CEO-founder Paul Jaminet. The company is led by CEO Marty J. Duvall (joined 2022) with Iain Dukes as Executive Chairman, Glen Weiss as CMO, and Shou-Ching Jaminet as CSO. The current revenue model is pre-commercial; Angiex has indicated it may pursue a global pharmaceutical partnership for worldwide commercialization similar to the Daiichi Sankyo/AstraZeneca ADC model, while retaining clinical development and manufacturing internally. To date, the company has raised approximately $76M+ in equity financing, including a $45M Series B led by Presight Capital with Peter Thiel participation (Aug 2021) and a $31M financing completed in November 2025 with Paulson Investment Company as placement agent.

Angiex firmographics

Firmographics
Name
Angiex
Legal name
Angiex Inc.
Website
https://angiex.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Angiex is a privately held, clinical-stage biopharmaceutical company developing first-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumors, with lead asset AGX101 currently in a US Phase 1 trial.
Ownership category
akta.pro rank

Angiex industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • Targeted cancer therapy
  • Vascular-targeted biotherapeutics
  • Clinical-stage biopharma

Where Angiex is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Angiex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Biopharmaceutical Development: Pre-revenue clinical-stage biopharmaceutical company. Angiex is developing AGX101 through Phase 1 clinical trials with the intent to commercialize the drug. The company has indicated it may pursue partnership with a global pharmaceutical company for marketing, sales, and distribution, similar to the Daiichi Sankyo/AstraZeneca model for ADCs, while retaining clinical development and manufacturing control internally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Angiex product offering

Product offering

Core offering

Angiex develops first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumor oncology, with lead asset AGX101 (a TM4SF1-directed ADC) currently in Phase 1 clinical trials in the United States. The proprietary Nuclear Delivery Platform delivers chemotherapeutic payloads directly to the nucleus of tumor cells and tumor vasculature endothelial cells via the TM4SF1 transport pathway, enabling dual attack on tumor blood vessels and tumor cells with three mechanisms of action (vascular injury, direct tumor cell killing, immune activation).

Product overview

Angiex is developing Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality. The company's lead product is AGX101, a first-in-class TM4SF1-directed ADC currently in Phase 1 clinical trials for solid tumors. AGX101 is built on Angiex's proprietary Nuclear Delivery Platform™ which exploits a novel TM4SF1 intracellular transport pathway to deliver payloads directly to the nucleus of tumor cells and tumor vasculature. The company also maintains a discovery-stage pipeline of additional ND-ADCs leveraging the same platform and target.

Differentiator

Problem solved

Functional benefit

Products and services

  • AGX101 First-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) for the treatment of solid cancers. Currently in Phase 1 clinical trials. Attacks both tumor cells and tumor vasculature through three mechanisms: vascular injury to deprive tumors of blood supply, activation of anti-tumor immunity, and direct killing of invasive and metastatic tumor cells. Targets TM4SF1, which is highly expressed in tumor cells and tumor vascular endothelial cells but limited in normal adult tissue.
  • Nuclear Delivery Platform Proprietary technology platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and endothelial cells of tumor blood vessels via TM4SF1's intracellular transport pathway. Enables creation of drugs for solid cancers with exceptional efficacy and therapeutic margin; protected by approximately a dozen patents on novel TM4SF1-directed ADC compositions and methods.
  • TM4SF1-Targeted Discovery Pipeline Discovery-stage pipeline of additional Nuclear-Delivered Antibody-Drug Conjugates beyond AGX101, leveraging the same TM4SF1 target and Nuclear Delivery Platform for multiple solid tumor indications.

Quantifiable outcome

  • Phase 1 dose-escalation and expansion trial initiated with first patient dosed August 7, 2024. Clinical site: NCT06440005 at multiple U.S. locations.
  • +6 more outcomes

Companies that use Angiex

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Angiex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Angiex partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • AbzenacoreTechnology or Integration · 9 August 2024Abzena, a global biopharmaceutical services provider and CDMO, provides critical clinical trial material manufacturing and bioconjugation services for Angiex's AGX101 Phase I clinical trial. Abzena's integrated services including cGMP manufacturing enabled Angiex to advance AGX101 into human trials. CEOs of both companies (Paul Jaminet of Angiex and Matthew Stober of Abzena) appeared jointly on the 'Chats with Chaudhrey' podcast discussing the collaboration.
  • Millipore-Sigma (BioReliance End-to-End Solutions)coreTechnology or Integration · 29 August 2017Millipore-Sigma collaborated with Angiex in August 2017 to support clinical readiness of Angiex's lead oncology ADC candidate. This was the first project at Millipore-Sigma's Massachusetts BioReliance End-to-End Solutions center. The collaboration gave Angiex access to end-to-end process development tools, GMP manufacturing process development, education programs, and training. Angiex CEO Paul Jaminet cited Millipore-Sigma's broad process development capabilities as key to accelerating the path to clinic.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Angiex competitors and assessment

Company assessment

Others

Direct peers

  • Mersana Therapeutics: Clinical-stage ADC company developing next-generation ADCs for solid tumors using proprietary Dolasynthen and Immunosynthen platforms. Closely comparable to Angiex in modality, stage, and solid tumor focus.

Broad incumbents

  • Daiichi Sankyo: Global ADC leader with Enhertu (DXd-ADC platform) partnered with AstraZeneca. Directly relevant as the model Angiex explicitly cites for its intended partnership/commercialization strategy and as the dominant player in solid-tumor ADCs.
  • AstraZeneca: Co-developer of Enhertu and Datroway ADCs with Daiichi Sankyo; the reference commercial partner cited by Angiex. Comparable as a large-cap oncology company with a major ADC franchise in solid tumors.
  • Pfizer: Major ADC player (Padcev) and historically developed a prior TM4SF1-directed ADC that AGX101 was designed to outperform by 10x in therapeutic margin. Highly relevant given direct prior work on the same target.
  • Gilead Sciences (Immunomedics): Acquired Immunomedics to commercialize Trodelvy, a leading solid-tumor ADC. Comparable as a large oncology company with an ADC franchise overlapping Angiex's solid-tumor setting.

Emerging players

  • Tubulis: Emerging clinical-stage ADC company developing differentiated solid-tumor ADCs using proprietary linker chemistries. Comparable in stage and technology-platform approach to Angiex.
  • ProfoundBio: Clinical-stage ADC developer with multiple solid-tumor programs in Phase 1/2. Comparable in stage, modality, and solid tumor focus.
  • Pyxis Oncology: Clinical-stage ADC and immuno-oncology company developing solid-tumor ADCs. Comparable as a similarly sized, similarly staged oncology biotech with platform-based ADC ambitions.
  • CytomX Therapeutics: Clinical-stage oncology company using a Probody platform to develop masked ADCs and immunotherapies for solid tumors. Comparable in modality, stage, and platform-disciplined pipeline approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Angiex social profiles

Digital presence

Angiex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Angiex leadership team

Management profile

Number of profiles

Profiles5 records

Angiex funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Angiex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angiex

What does Angiex do?

Angiex develops first-in-class Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs) for solid tumor oncology, with lead asset AGX101 (a TM4SF1-directed ADC) currently in Phase 1 clinical trials in the United States. The proprietary Nuclear Delivery Platform delivers chemotherapeutic payloads directly to the nucleus of tumor cells and tumor vasculature endothelial cells via the TM4SF1 transport pathway, enabling dual attack on tumor blood vessels and tumor cells with three mechanisms of action (vascular injury, direct tumor cell killing, immune activation).

Is Angiex a public or private company?

Angiex is a private company. It is classified as venture growth investor backed and is currently operating.

When was Angiex founded?

Angiex was founded in 2015. It employs 1 to 10 people.

Where is Angiex based?

Angiex is headquartered in Cambridge, United States, in the North America region.

How does Angiex make money?

One revenue line is on record: biopharmaceutical Development.

Who are Angiex's main competitors?

ImmunoGen (AbbVie) is listed as an others. Mersana Therapeutics is listed as a direct peer. Broad incumbents are Daiichi Sankyo, AstraZeneca, Pfizer and Gilead Sciences (Immunomedics). Emerging players are Tubulis, ProfoundBio, Pyxis Oncology and CytomX Therapeutics.

Does Angiex have an API?

No public API is recorded for Angiex.

What industry is Angiex in?

Angiex's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechNatera teams with Angiex on cancer drug trial monitoringNatera partnered with Angiex to evaluate its Signatera blood test in a phase 1 trial of AGX101, a cancer drug targeting TM4SF1. The collaboration aims to complement imaging when viable tumor remains uncertain. Financial terms were not disclosed.EIN PresswireAngiex Reports AACR In Vivo Data Supporting AGX101 in Combination With Immune Checkpoint Inhibitors for Solid TumorsAngiex will present preclinical in vivo data at the AACR 2026 meeting on AGX101 combined with immune checkpoint inhibitors. The data suggest AGX101 may enhance checkpoint inhibitor activity through selective targeting of tumor vasculature, supporting further investigation in selected tumor types and combination settings.GlobeNewswireAngiex Completes Financings Totaling $31 Million to Advance Phase 1 Dose Escalation of Nuclear-Delivered ADC AGX101 in Patients with Advanced Solid TumorsAngiex Inc., a Cambridge-based biotech developing nuclear-delivered antibody-drug conjugate therapies for solid cancers, has completed financings totaling $31 million with participation from new and existing investors. The proceeds will advance AGX101, a first-in-class TM4SF1-directed ND-ADC, through Phase 1 dose-escalation clinical trials assessing safety, tolerability, and preliminary anti-tumor activity in solid tumor patients. Paulson Investment Company acted as placement agent for the $16 million equity offering, and funds will also support evaluating AGX101 in combination with immune checkpoint inhibitors.AngiexAngiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101Angiex Inc. announced completion of financings totaling $31 million and dosing of the first patient in the Phase 1 clinical trial of AGX101, a first-in-class TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate therapy for patients with advanced solid tumors. The dose-escalation study is designed to assess safety, tolerability, and preliminary anti-tumor activity with doses up to 10 mg/kg. The funds will support advancing AGX101 through the trial endpoints and evaluating it in combination with immune checkpoint inhibitors.openPR.comGlobal Space Medicine Market Generated Opportunities, Future Scope 2025-2032 | SpacePharma, Angiex, INC, ICECUBES, Merck & Co., IncThe global space medicine market is projected to grow from USD 948.7 million in 2025 to USD 1,969.7 million by 2032, a CAGR of 11%. The report by Coherent Market Insights covers segmentation by type, application, and end-user, and regional analysis across major markets.ContractpharmaAngiex Initiates Phase 1 Clinical Trial of AGX101Angiex has initiated patient dosing for the Phase 1 clinical trial of AGX101, a first-in-class TM4SF1-directed Antibody-Drug Conjugate designed to target solid tumors. The company partnered with Abzena to handle the development, manufacturing, and supply of the clinical trial material required for this study.Clinical Trials ArenaAngiex doses first patient in Phase I trial for solid cancers therapy AGX101Angiex has dosed the first patient in its Phase I open-label study of AGX101, a nuclear-delivered antibody-drug conjugate targeting TM4SF1 for solid cancers. The trial aims to evaluate safety, pharmacokinetics, and preliminary efficacy while determining the recommended dose for future Phase II studies. This milestone follows investigational new drug clearance from the US FDA in November 2023.PR NewswireAbzena Supplies Clinical Trial Material for Angiex's Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADCAngiex began patient dosing for its Phase 1 trial of AGX101, a first-in-class TM4SF1-directed ADC, with Abzena supplying clinical trial material. The open-label study assesses safety, PK, PD, and anti-tumor activity, with dose escalation up to 10 mg/kg. Abzena will continue supporting development to accelerate the treatment's availability.GlobeNewswireAngiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid TumorsAngiex announced the first patient has been dosed in the Phase 1 clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate for solid tumors. The open-label, dose-escalation and expansion study will assess safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity, with doses up to 10 mg/kg in the escalation portion.